NASDAQ:PCYC - Pharmacyclics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases. Receive PCYC News and Ratings via Email Sign-up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:PCYC Previous Symbol CUSIP71693310 CIK949699 WebN/A Phone+1-302-6587581Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions What is Pharmacyclics' stock symbol? Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC." Has Pharmacyclics been receiving favorable news coverage? Media coverage about PCYC stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pharmacyclics earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. What other stocks do shareholders of Pharmacyclics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmacyclics investors own include Celgene (CELG), Gilead Sciences (GILD), Baidu (BIDU), Regeneron Pharmaceuticals (REGN), Jazz Pharmaceuticals (JAZZ), Netflix (NFLX), Biogen (BIIB), Intercept Pharmaceuticals (ICPT), Vertex Pharmaceuticals (VRTX) and salesforce.com (CRM). How do I buy shares of Pharmacyclics? Shares of PCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Pharmacyclics? Pharmacyclics' mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581. MarketBeat Community Rating for Pharmacyclics (NASDAQ PCYC)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 458 (Vote Outperform)Underperform Votes: 391 (Vote Underperform)Total Votes: 849MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe PCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCYC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/25/2019 by MarketBeat.com StaffFeatured Article: What is the QQQ ETF?